Pharmaceuticals, Biotechnology & Life Sciences

Pfizer’s $10.5 B oncology deals with Innovent and I‑Mab plus Lorbrena’s seven‑year CROWN data promise growth but raise milestone, regulatory and pricing risks that investors must weigh.

Replimune Group Inc. pioneers oncolytic immunotherapy, aiming to selectively kill cancer cells while sparing healthy tissue. Learn about its clinical trials, market performance, and future oncology impact.

Shenzhen Salubris Pharmaceuticals: 374.5 billion‑CNY cap, 55.95 P/E, and robust R&D drive shows its strategic edge in tablets, capsules, and injectables – poised for future growth.

Satellos Bioscience, Toronto‑based biotech, advances SAT‑3247 for muscular dystrophy, with Phase II trials and investor talks at key conferences.

BriaCell’s Phase III Bria‑ABC study gets sixth consecutive DSMB endorsement, confirming safety and paving the way for fast‑track approval in metastatic breast cancer.

Pfizer’s silent insiders, strong dividend yield, and FDA vaccine outlook paint a clear picture: a steady, income‑focused stock amid regulatory shifts and analyst optimism.

Q‑C Technologies Inc. faces steep stock volatility, a negative P/E, and financial uncertainty despite promising drug‑development goals in aging, pain and sleep disorders.

Strides Pharma Science’s latest SEBI filing confirms no new share encumbrances, underscoring its commitment to transparency, market confidence, and regulatory compliance.

Discover how Kuros Biosciences AG’s orthobiologic innovations target bone defects, boost regeneration, and drive high‑growth potential in Swiss and U.S. markets.

Immunic’s new CEO, Erik Lundgren, aligns with the upcoming Phase‑2 CALLIPER data on Vidofludimus Calcium, promising a boost in MS therapy prospects and investor confidence.